{"id":654603,"date":"2023-06-07T13:10:01","date_gmt":"2023-06-07T13:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=654603"},"modified":"2023-06-07T13:10:01","modified_gmt":"2023-06-07T13:10:01","slug":"complicated-skin-and-soft-tissue-infections-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-stempeutics-angiocrine-bioscience-carephar","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/complicated-skin-and-soft-tissue-infections-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-stempeutics-angiocrine-bioscience-carephar_654603.html","title":{"rendered":"Complicated Skin And Soft Tissue Infections Clinical Trials | A Drug Pipeline Analysis Report 2023 Companies &#8211; Stempeutics, Angiocrine Bioscience, Carephar"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Complicated Skin And Soft Tissue Infections Clinical Trials | A Drug Pipeline Analysis Report 2023 Companies - Stempeutics, Angiocrine Bioscience, Carephar\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Complicated Skin And Soft Tissue Infections Clinical Trials | A Drug Pipeline Analysis Report 2023 Companies - Stempeutics, Angiocrine Bioscience, Carephar\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Nevada, Las Vegas United States) DelveInsight\u2019s \u201cComplicated Skin And Soft Tissue Infections- Pipeline Insight, 2023\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Complicated Skin And Soft Tissue Infections pipeline landscape.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/complicated-skin-and-soft-tissue-infections-cssti-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Takeaways from the Complicated Skin And Soft Tissue Infections Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Over 5+ companies and 5+ pipeline drugs in Alpha1-Antitrypsin Deficiency (AATD) pipeline landscape and their anticipated acceptance in the Complicated Skin And Soft Tissue Infections market would significantly increase market revenue.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading Complicated Skin And Soft Tissue Infections companies developing novel drug candidates to improve the Complicated Skin And Soft Tissue Infections treatment landscape include Stempeutics, Angiocrine Bioscience, CarepharOssium Health and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Promising Complicated Skin And Soft Tissue Infections pipeline therapies in various stages of development include Mitapivat and others&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Complicated Skin And Soft Tissue Infections Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">A Complicated Skin And Soft Tissue Infections is a small tunnel that develops between the end of the bowel and the skin near the anus (where poo leaves the body). They&#8217;re usually the result of an infection near the anus causing a collection of pus (abscess) in the nearby tissue. When the pus drains away, it can leave a small channel behind. Complicated Skin And Soft Tissue Infectionss can cause unpleasant symptoms, such as discomfort and skin irritation, and will not usually get better on their own. Surgery is recommended in most cases.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Symptoms of an Complicated Skin And Soft Tissue Infections can include skin irritation around the anus, a constant, throbbing pain that may be worse when a person sits down, move around, poo or cough, smelly discharge from near the anus, passing pus or blood when a person has to poo, swelling and redness around the anus and a high temperature (fever) if the person also have an abscess. Most Complicated Skin And Soft Tissue Infectionss develop after an anal abscess. One can get one if the abscess does not heal properly after the pus has drained away. Less common causes of Complicated Skin And Soft Tissue Infectionss include Crohn&#8217;s disease, diverticulitis, hidradenitis suppurativa, infection with tuberculosis (TB) or HIV, or a complication of surgery near the anus.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/60b33781e91b289af3c31f5c21e083e5.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Complicated Skin And Soft Tissue Infections&nbsp; Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Stempeucel: Stempeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Stempeucel is a flagship product. It is an on-demand, off-the-shelf product based on pooled, allogeneic Mesenchymal Stromal Cells derived from the bone marrow of healthy, adult volunteers. In August 2020, the Drug Controller General of India (DCGI) granted manufacturing and marketing approval for Stempeucel product for the treatment of CLI due to Buerger&rsquo;s Disease and CLI due to Atherosclerotic Peripheral Arterial Disease. Stempeucel&reg; becomes the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved Globally for CLI indication. Stempeucel&reg; is being developed for the treatment of Knee Osteoarthritis, Diabetic Foot Ulcer, PeriComplicated Skin And Soft Tissue Infections (PAF), and Acute Respiratory Distress Syndrome due to COVID-19 pneumonia. An open-label, single-arm, investigator-initiated Phase I\/II study to assess the safety and efficacy of local administration of Stempeucel&reg; in Patients with perianal fistulizing Crohn&#8217;s disease.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Discover more about the emerging Complicated Skin And Soft Tissue Infections drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/complicated-skin-and-soft-tissue-infections-cssti-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Complicated Skin And Soft Tissue Infections Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Complicated Skin And Soft Tissue Infections Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Stempeucel: Stempeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight&rsquo;s Report covers around 5+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I) along with the details of<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Alpha1-Antitrypsin Deficiency (AATD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intra-articular<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intraocular<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intrathecal<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ophthalmic<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Transdermal<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Products have been categorized under various Molecule types such as<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oligonucleotide<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptide<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Drugs have been categorized under various product types like mono, Combination, and Mono\/Combination.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Scope of the Complicated Skin And Soft Tissue Infections&nbsp; Pipeline Report&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage:&nbsp;Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Alpha1 Antitrypsin Deficiency Companies:&nbsp; Stempeutics, Angiocrine Bioscience, Carephar, Ossium Health, and others.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Complicated Skin And Soft Tissue Infections&nbsp; Pipeline Therapies: Stempeucel and others&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Find out more about the Complicated Skin And Soft Tissue Infections treatment options in development @<strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/complicated-skin-and-soft-tissue-infections-cssti-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Complicated Skin And Soft Tissue Infections Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Complicated Skin And Soft Tissue Infections Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Complicated Skin And Soft Tissue Infections Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Complicated Skin And Soft Tissue Infections Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Complicated Skin And Soft Tissue Infections Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Complicated Skin And Soft Tissue Infections Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Complicated Skin And Soft Tissue Infections Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Complicated Skin And Soft Tissue Infections Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Complicated Skin And Soft Tissue Infections Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Complicated Skin And Soft Tissue Infections Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Complicated Skin And Soft Tissue Infections Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Complicated Skin And Soft Tissue Infections Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Complicated Skin And Soft Tissue Infections Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Complicated Skin And Soft Tissue Infections Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Complicated Skin And Soft Tissue Infections Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=complicated-skin-and-soft-tissue-infections-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-stempeutics-angiocrine-bioscience-carephar\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=complicated-skin-and-soft-tissue-infections-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-stempeutics-angiocrine-bioscience-carephar\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP (Nevada, Las Vegas United States) DelveInsight\u2019s \u201cComplicated Skin And Soft Tissue Infections- Pipeline Insight, 2023\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Complicated Skin And Soft Tissue Infections pipeline landscape. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/complicated-skin-and-soft-tissue-infections-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-stempeutics-angiocrine-bioscience-carephar_654603.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-654603","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/654603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=654603"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/654603\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=654603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=654603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=654603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}